Moderna, Inc. (23)

Browse by Contract Category

Contracts

Amended and Restated Non-Employee Director Compensation Policy, effective April 28, 2021 (Filed With SEC on May 6, 2021)
Amendment No. 7, dated March 12, 2021, to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as... (Filed With SEC on May 6, 2021)
Amendment No. 6, dated February 16, 2021 (Filed With SEC on May 6, 2021)
Description of Capital Stock (Filed With SEC on February 26, 2021)
Fifth Amendment to Lease, by and between ModernaTx, Inc. and ARE-Tech Square, LLC dated as of August 28, 2019 (Filed With SEC on November 6, 2019)
Form of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Stock Option and Incentive Plan (Filed With SEC on May 6, 2021)
Amendment No. P00003 to Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated December 11, 2020 (Filed With SEC on February 26, 2021)
Amended and Restated Executive Retention Agreement by and between the Company and Tal Zaks, dated as of February 23, 2021 (Filed With SEC on February 26, 2021)
Award Contract No. W911QY20C0100, by and between Moderna US Inc. and the Army Contracting Command of the U.S. Department of Defense, dated August 9, 2020, as amended September 8,... (Filed With SEC on October 30, 2020)
Global Long Term Agreement, by and among ModernaTX Inc., Lonza Sales Ltd., and Lonza Ltd., dated September 4, 2020 (Filed With SEC on October 30, 2020)
Agreement No. HHSO100201600029C, by and between the Company and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020, as amended on May 24, 2020,... (Filed With SEC on October 30, 2020)
Offer Letter by and between the Company and David W. Meline, dated as of June 3, 2020 (Filed With SEC on August 6, 2020)
Agreement No. HHSO100201600029C, by and between the Company and the Biomedical Advanced Research and Development Authority, dated as of April 16, 2020, as amended (Filed With SEC on August 6, 2020)
Underwriting Agreement, dated as of May 18, 2020, by and between Moderna, Inc. and Morgan Stanley & Co. LLC (Filed With SEC on May 20, 2020)
Executive Retention and Separation Agreement, dated May 5, 2020, by and between Moderna, Inc. and Lorence Kim, M.D (Filed With SEC on May 7, 2020)
Executive Retention Agreement, dated March 29, 2020, by and between Moderna, Inc. and Tal Zaks, M.D (Filed With SEC on March 30, 2020)
Offer Letter by and between the Company and Juan Andres, dated as of March 16, 2017 (Filed With SEC on February 27, 2020)
Offer Letter by and between the Company and Tal Zaks, dated as of February 17, 2015 (Filed With SEC on February 27, 2020)
Description of Capital Stock (Filed With SEC on February 27, 2020)
Underwriting Agreement, dated as of February 11, 2020, by and among Moderna, Inc. and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters (Filed With SEC on February 12, 2020)
Fifth Amendment to Collaboration and License Agreement by and between ModernaTX, Inc. and Merck Sharp & Dohme Corp., dated as of May 3, 2019 (Filed With SEC on August 8, 2019)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 9, 2019)
Strategic Advisor & Transition Agreement by and between ModernaTX, Inc. and John Mendlein, dated as of January 17, 2019 (Filed With SEC on March 13, 2019)